Lung Transplantation: Planning Grants for Clinical Trials of Novel Therapies (R34)

Post Date

September 30th 2009

Application Due Date

February 3rd 2010

Funding Opportunity Number

RFA-HL-10-016

CFDA Number(s)

93.838

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1500000

• Award Range:

  $None - $450000

Grant Description

Purpose. The National Heart, Lung, and Blood Institute (NHLBI) invites applications to support the initial organization, protocol development, and necessary preliminary studies critical for the design of robust clinical trials in lung transplantation. This Funding Opportunity Announcement (FOA) should be used to position investigators or groups of investigators to develop competitive clinical trials to test important new strategies to enhance the quality of lungs available for transplant and improve management and long term outcomes of lung transplant recipients. This may include assembling a research team, consisting of a principal clinical site and having several collaborating ancillary sites, defining and prioritizing research questions, collecting information on the feasibility of the therapy and patient availability, and developing protocol(s). Applications must demonstrate that the proposed work is both necessary and sufficient to permit proceeding to the design of important clinical trial(s). During the evaluation of applications in response to this FOA, the review group will also consider the significance and potential impact of the full-scale clinical trial(s) that would be proposed following the R34 award period. Of most importance, the NHLBI anticipates that the R34 award period will yield competitive investigator-initiated clinical trial grant applications that evaluate interventions for the treatment of complications during and after lung transplantation. Mechanism of Support. This FOA will utilize the R34 grant mechanism. Funds Available and Anticipated Number of Awards. The NHLBI intends to commit approximately $1,500,000 total costs for FY2010. The total amount to be awarded for this program will be a maximum of $3,000,000 total costs for the 2-year project period. It is anticipated that NHLBI will fund up to 2 awards.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-10-016.html